|Page (1) of 1 - 05/15/18||email article||print page|
(May 15, 2018)
Dublin, May 15, 2018 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering.
The HNC Asia-Pacific market will be valued at $424.5m in 2023, growing from $265.9m in 2016 at a CAGR of 6.9%.
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter